It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »
The News: US Food and Drug Administration chief Scott Gottlieb on Thursday (May 3, 2018) questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law,… Read more »
The News: Rising healthcare stocks and fading qualms over an escalating Syrian conflict had Wall St. optimistic to start the week. Stocks had ended lower on Friday (April 13, 2018)… Read more »
